Latest: FDA Approves New Biosimilar for Oncology Treatment
Healthcare Business

Age, BTKi Use May Contribute to Cardiovascular Risk in CLL

by American Journal Managed Care
0 Comments
0 Mins
Despite the findings, existing data around cardiovascular risk in chronic lymphocytic leukemia (CLL) are limited, and more comprehensive information is needed to draw strong conclusions.
Tags:
American Journal Managed Care
Author

American Journal Managed Care

Previous Post
Clinical Perspectives in Current and Emerging CAR T Therapies for Early R/R MM
Next Post
Lilly says breast cancer drug extended survival in study
📢

Advertisement

300x250 Banner

Recent Content

COPD Biologics: Early Treatment Insights

Pulmonology • 2 hours ago

Antihypertensive Medication Guidelines

Cardiology • 4 hours ago

Juvenile Arthritis Care Transition

Rheumatology • 6 hours ago